Breathe Well Live Well
|
Merck Announces Presentation of Phase III Investigational Studies Evaluating …
MarketWatch (press release) DULERA is indicated in the United States for the treatment of asthma in patients 12 years and older.(1) It is not indicated for the relief of acute bronchospasm or for the treatment of COPD. A supplemental new drug application (sNDA) for DULERA for the … |
View full post on asthma – Google News
|
Merck Announces Recipients of the 2011 "Will to Win"
CSRwire.com (press release) WHITE HOUSE STATION, NJ, Oct. 11 /CSRwire/ – Merck today announced the names of 10 outstanding high school seniors with asthma who have been selected as recipients of the 2011 Will to Win Scholarships. Each student has been awarded a $5000 scholarship … |
View full post on asthma – Google News
|
Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide …
MarketWatch (press release) AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. In this double-blind, placebo-controlled study, … |
View full post on asthma – Google News
|
Trident Pharmaceuticals Announces Initiation Of Phase 1a
Pharmaceutical Online (press release) HF1020 is believed to offer a novel approach for treating the underlying inflammatory pathology of autoimmune disease and allergic asthma, without causing systemic immunosupression. HF1020 is an oral biopharmaceutical product which acts by inducing … |
View full post on asthma – Google News
|
Trident Pharmaceuticals Announces Initiation of Phase 1a Clinical Study of HF1020
MarketWatch (press release) HF1020 is believed to offer a novel approach for treating the underlying inflammatory pathology of autoimmune disease and allergic asthma, without causing systemic immunosupression. HF1020 is an oral biopharmaceutical product which acts by inducing … |
View full post on asthma – Google News
|
AB Science Announces That FDA Authorization (IND) Has Been Granted for the …
EON: Enhanced Online News (press release) For the record, severe persistent asthma uncontrolled with oral corticosteroids is a disease that has no registered treatment and all the immunosuppressant and biologic drugs tested to date have failed. Masitinib is therefore the only drug candidate in … |
View full post on asthma – Google News
|
AB Science Announces That FDA Authorization (IND) Has Been Granted for the …
MarketWatch (press release) For the record, severe persistent asthma uncontrolled with oral corticosteroids is a disease that has no registered treatment and all the immunosuppressant and biologic drugs tested to date have failed. Masitinib is therefore the only drug candidate in … |
View full post on asthma – Google News
|
Government announces COPD and asthma strategy
Nursing Times The government outcomes strategy for Chronic Obstructive Pulmonary Disease (COPD) and asthma is intended to improve the lives of patients with breathing difficulties by coordinating the efforts of the NHS, social care and voluntary organisations. … |
View full post on asthma – Google News
|
ACAAI Announces Free Screenings for Asthma Awareness Month
About .com: Ear, Nose and Throat Disorders During the month of May, (Asthma Awareness Month), the American College of Asthma, Allergies and Immunology (ACAAI) is offering free asthma screenings. They'd also like you to know, that you may have … A Sharp Rise of Asthma in the US |
View full post on asthma – Google News
|
Govt announces plan to reduce health disparities
The Associated Press In between, they're more likely to suffer from a host of illnesses such as diabetes, heart disease, kidney disease and asthma. Part of the problem is access to care: Minorities make up more than half of the 50 million people who are uninsured, … |
View full post on asthma – Google News